Marijuana And Cannabinoids: A Neuroscience Research Summit

Donnybrook

Well-Known Member
Marijuana And Cannabinoids: A Neuroscience Research Summit



by Rick Thompson





This is a notice of a conference of significance in the medical cannabis field. The Research Summit will be held on March 22-23 at the Natcher Conference Center on the National Institutes of Health campus in Bethesda, Maryland.

After viewing the advertisement for the event I question the premise, as the cannabinoid system itself has no adverse effects; the phrasing of the event’s summary implies a bias toward finding harm, a charge that Dr. Sanjay Gupta and other have levied against the NIH and NIDA for some time.

The discussions will include a Michigan contingent, as Dr. Christine Rabinak from Wayne State University will participate in the section reserved for Therapeutic Potential: Epilepsy, Multiple Sclerosis, Pain, PTSD/Anxiety.

She was the lead author on a paper published in 2013 regarding marijuana use and PTSD.

www.ncbi.nlm.nih.gov/pmc/articles/PMC3445738/

Marijuana and Cannabinoids: A Neuroscience Research Summit is being convened by the National Institutes of Health (NIH), which will focus on the neurological and psychiatric effects of marijuana, other cannabinoids, and the endocannabinoid system. Both the adverse and the potential therapeutic effects of the cannabinoid system will be discussed. The goal of this summit is to ensure evidence-based information is available to inform practice and policy, particularly important at this time given the rapidly shifting landscape regarding the recreational and medicinal use of marijuana.
The meeting is being sponsored by several NIH Institutes and Centers: the National Institute on Drug Abuse(NIDA); the National Institute on Alcohol Abuse and Alcoholism (NIAAA); the National Center for Complementary and Integrative Health (NCCIH); the National Institute of Mental Health (NIMH); and theNational Institute of Neurological Disorders and Stroke (NINDS).



Speakers:
Understanding the Endocannabinoid System

Benjamin Cravatt, Ph.D.
The Scripps Research InstituteKen Mackie, M.D.
Indiana UniversityDaniele Piomelli, Ph.D., Pharm.D.
University of California, Irvine
Brain Development and Function

Susan Tapert, Ph.D.
University of California, San DiegoKent Hutchison, Ph.D.
University of Colorado BoulderMadeline Meier, Ph.D.
Arizona State University
Psychosis, Addiction, and Alcohol Interactions

Anne Eden Evins, M.D., M.P.H.
Massachusetts General HospitalAlan Budney, Ph.D.
Geisel School of Medicine at DartmouthLarry Parsons, Ph.D.
The Scripps Research Institute
Psychomotor Performance and Detection

Marilyn Huestis, Ph.D.
National Institute on Drug Abuse
Therapeutic Potential: Epilepsy, Multiple Sclerosis, Pain, PTSD/Anxiety

Ivan Soltesz, Ph.D.
Stanford UniversityAmy Brooks-Kayal, M.D.
Children’s Hospital ColoradoDavid Gloss, M.D., M.P.H.
Charleston Area Medical CenterAndrea G. Hohmann, Ph.D.
Indiana University
Barth Wilsey, M.D.
University of California, San Diego

Cecilia Hillard, Ph.D.
Medical College of Wisconsin

Christine Rabinak, Ph.D.
Wayne State University

Policy-Related Research

Rosalie Liccardo Pacula, Ph.D.
RAND CorporationMark Kleiman, Ph.D., M.P.P.
NYU Marron Institute of Urban Management
Please visit the website for detailed security and location information.

apps1.seiservices.com/nih/mj/2016/Default.aspx
 

qwizoking

Well-Known Member
I question the premise, as the cannabinoid system itself has no adverse effect
Both the adverse and the potential therapeutic effects of the cannabinoid system will be discussed.


Thats inaccurate, as you say its a system. Whos function is not benign. It has important roles in our daily functioning of the body and brain. Besides a general understanding of how things work we can see/study these affects exaggerated in cb knockout mice for example or singling out receptors with a selective full agonist and then moving forward. Activating ANY receptor has effect obviously, wether this is therapeutic is constrained to the individual. An adverse affect of opiate use is euphoria, slowed movement in the gut and increased levels of estrogen etc. Much more complicated than opiate receptors were hit and so pain relieved. In the same way, a high is not the only side effect of activating our endocannabinoid system
 
Top